// App-Quantinova.ai

165 : Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Helena Marzo-Ortega

  • Airi Poder

  • Filip Van den Bosch

  • Jurgen Wollenhaupt

  • Eric Lespessailles

  • Lichen Teng

  • Stephen Hall

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Rheumatology, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals & University of Leeds, Leeds, UNITED KINGDOM

  • Dermatovenerology, Clinical Research Centre Ltd, Tartu, ESTONIA

  • Rheumatology, UZ Gent, Gent, BELGIUM

  • Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, GERMANY

  • Rheumatology, University of Orléans, Orleans, FRANCE

  • Biostatistics, Celgene Corporation, Summit, NJ, USA

  • Rheumatology, Monash University, CabriniHealth, Melbourne, AUSTRALIA

Locations

  • United States

  • United Kingdom

  • Estonia

  • Belgium

  • Germany

  • France

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved